色瑞替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌的研究概况(5)
[13] KATAYAMA R，FRIBOULET L，KOIKE S，et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib[J]. Clin Cancer Res，2014，20(22)：5686-5696.[14] DONG X，FERNANDEZ-SALAS E，LI E，et al. Elucidation of resistance mechanisms to second-generation ALK inhibitors alectinib and ceritinib in non-small-cell lung cancer cells[J]. Neoplasia，2016 ......
您现在查看是摘要页，全文长 3487 字符。